Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03045029 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Study acronym: ADAPT
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 2025 to Mar 2027v19
  2. Primary completion date: Apr 7, 2022 to Dec 2025 Completion date: Dec 2023 to Dec 2025v18 Show 1 more changeShow less
    • Completion date: Dec 2023 to Dec 2025
  3. Completion date: Jun 2023 to Dec 2023v17
  4. Completion date: Dec 2022 to Jun 2023v16
  5. Trial status: Recruiting to Active, Not Recruiting Primary completion date changed from estimate of Jun 2022 to Apr 7, 2022 · Completion date: Jun 2022 to Dec 2022 · Site details revised at 41 of 41 sitesv15 Show 3 more changesShow less
    • Primary completion date changed from estimate of Jun 2022 to Apr 7, 2022
    • Completion date: Jun 2022 to Dec 2022
    • Site details revised at 41 of 41 sites
Show 13 earlier versionsHide 13 earlier versions
  1. 2 versions Re-verified since Mar 26, 2021, no change to tracked fieldsv13-v14
  2. Primary and study completion dates: Jun 2020 to Jun 2022 Study sites: 44 to 41v12 Show 1 more changeShow less
    • Study sites: 44 to 41
  3. Study sites: 43 to 44v11
  4. Study sites: 35 to 43v10
  5. Study sites: 40 to 35v9
  6. Primary and study completion dates: Jan 2019 to Jun 2020 Eligibility criteria expanded, about 26 words · Secondary endpoints: 6 to 8v8 Show 2 more changesShow less
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: 6 to 8

    See this version in full on ClinicalTrials.gov ↗

  7. Study sites: 25 to 40v7
  8. Study sites: 13 to 25 Primary and study completion dates: Jun 2019 to Jan 2019v6 Show 1 more changeShow less
    • Primary and study completion dates: Jun 2019 to Jan 2019
  9. Study sites: 1 to 13v5
  10. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jul 2017 to Jul 18, 2017v4 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 2017 to Jul 18, 2017
  11. Start date: Jun 2017 to Jul 2017v3
  12. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
United Therapeutics
13 trials monitored
See 2 trials at risk
Hypertension
1,795 trials monitored
See 85 trials at risk
This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation
Trial Details
NCT Number NCT03045029
Lead Sponsor United Therapeutics
Conditions Pulmonary Arterial Hypertension
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov